Nanjing King-Friend Biochemical Pharmaceutical (603707.SH): Vitamin B12 injection receives drug registration approval from the US FDA.
Jikeyong Co., Ltd. (603707.SH) issued an announcement that the company recently received a notice from the U.S. Food and Drug Administration (FDA)...
Nanjing King-Friend Biochemical Pharmaceutical (603707.SH) announced that the company recently received approval from the U.S. Food and Drug Administration (FDA) for the Vitamin B12 Injection, 1000mcg/mL, 10,000mcg/10mL (1,000mcg/mL), 30,000mcg/30mL (1,000mcg/mL) (ANDA number: 214316).
As of now, the company has invested approximately 27.0121 million RMB in the research and development of the Vitamin B12 Injection project. The newly approved product will be launched in the U.S. market in the near future, and is expected to have a positive impact on the company's business performance.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
